Pharmacogenetics to Predict Adverse Events Associated With Antidepressants

Area of Science:

• Pharmacogenomics
• Pediatric Clinical Pharmacology
• Drug Metabolism

Background:

• Cytochrome P450 2C19 (CYP2C19) metabolizer status influences drug efficacy and safety.
• Understanding these associations in pediatric populations is crucial for optimizing antidepressant therapy.
• Previous studies have primarily focused on adult populations.

Purpose of the Study:

• To investigate the relationship between CYP2C19 metabolizer status and adverse events (AEs) associated with sertraline and escitalopram/citalopram ((es)citalopram) in children.
• To determine if pediatric-specific pharmacogenetic differences impact antidepressant safety.
• To inform genotype-guided prescribing practices for pediatric patients.

Main Methods:

• Retrospective cohort study utilizing electronic health records linked to DNA data.
• Included children ≤18 years with documented exposure to (es)citalopram or sertraline.
• CYP2C19 functional variants genotyped to assign metabolizer status (normal, intermediate, poor); AEs assessed via chart review; Cox regression used for association analysis.

Main Results:

• Sertraline AEs were more frequent in normal metabolizers (NMs) compared to poor (PMs) or intermediate metabolizers (IMs) in children (adjusted HR 1.9; P = .04).
• (Es)citalopram AEs showed a trend towards higher incidence in NMs but did not reach statistical significance (adjusted HR 1.6; P = .08).
• Findings suggest a potential pediatric-specific effect of CYP2C19 status on sertraline-related AEs.

Conclusions:

• CYP2C19 normal metabolizers in the pediatric cohort exhibited increased sertraline AEs, contrasting with adult data.
• No significant association was found between CYP2C19 status and (es)citalopram AEs in children.
• Further research is needed to elucidate the mechanisms behind these pediatric-specific findings and guide clinical practice.